KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Petrylak, D. P. [1 ]
Li, B. [2 ]
Schloss, C. [2 ]
Fizazi, K. [3 ]
机构：
[1] Yale Univ, Smilow Canc Hosp, Med Oncol, New Haven, CT USA
[2] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[3] Gustave Roussy, Canc Med, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
891TiP
引用
收藏
页码：351 / 351
页数：1
相关论文
共 50 条
  • [21] Biomarker analysis of men with enzalutamide (enza)resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) plus enza in KEYNOTE-199
    Graff, J. N.
    Tagawa, S.
    Hoimes, C.
    Gerritsen, W.
    Vaishampayan, U. N.
    Elliott, T.
    Hwang, C.
    Ten Tije, A. J.
    Omlin, A. G.
    McDermott, R. S.
    De Wit, R.
    Qiu, P.
    Poehlein, C.
    Kim, J.
    Suttner, L.
    Cristescu, R.
    Marton, M. J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S383 - S383
  • [22] Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
    Fong, Peter C. C.
    Retz, Margitta
    Drakaki, Alexandra
    Massard, Christophe
    Berry, William R.
    Romano, Emanuela
    De Bono, Johann S.
    Feyerabend, Susan
    Appleman, Leonard Joseph
    Conter, Henry Jacob
    Sridhar, Srikala S.
    Shore, Neal D.
    Linch, Mark David
    Joshua, Anthony M.
    Gurney, Howard
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Todenhofer, Tilman
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Byun, Seok-Soo
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [24] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
    Arranz Arija, J. A.
    Yu, E. Y.
    Piulats, J. M.
    Gravis, G.
    Laguerre, B.
    Oudard, S.
    Fong, P. C.
    Kolinsky, M. P.
    Augustin, M.
    Todenhofer, T.
    Kam, A. E.
    Gurney, H.
    Tafreshi, A.
    Retz, M.
    Berry, W. R.
    Mar, N.
    Wu, H.
    Qiu, P.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S513 - S514
  • [25] Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5
    Graff, Julie Nicole
    Antonarakis, Emmanuel S.
    Hoimes, Christopher J.
    Tagawa, Scott T.
    Hwang, Clara
    Kilari, Deepak
    Ten Tije, A. J.
    Omlin, Aurelius Gabriel
    McDermott, Raymond S.
    Vaishampayan, Ulka N.
    Elliott, Anthony
    Wu, Helen
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
    Petrylak, D. P.
    Shore, N. D.
    Bennamoun, M.
    Ratta, R.
    Piulats, J. M.
    Li, B.
    Schloss, C.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1332 - S1333
  • [27] KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
    Hoimes, Christopher J.
    Graff, Julie N.
    Tagawa, Scott T.
    Hwang, Clara
    Kilari, Deepak
    Ten Tije, A. J.
    Omlin, Aurelius
    McDermott, Raymond S.
    Vaishampayan, Ulka N.
    Elliott, Tony
    Gerritsen, Winald R.
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)
    Todenhoefer, T.
    Piulats, J. M.
    Ferrario, C.
    Linch, M. D.
    Stoeckle, M.
    Laguerre, B.
    Arranz, J. A.
    Fong, P. C. C.
    Berry, W. R.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A. M.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    De Bono, J. S.
    Yu, E. Y.
    EUROPEAN UROLOGY, 2022, 81 : S789 - S790
  • [29] KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arija, Jose Angel Arranz
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Feyerabend, Susan
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [30] Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
    Vaishampayan, U. N.
    Elliott, T.
    Omlin, A. G.
    Graff, J. N.
    Hoimes, C. J.
    Tagawa, S. T.
    Hwang, C.
    Kilari, D.
    Ten Tije, A. J.
    McDermott, R. S.
    Gerritsen, W. R.
    Wu, H.
    Kim, J.
    Schloss, C.
    de Bono, J. S.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1330 - S1330
12345